The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes

Cancer is the second leading cause of death in people with chronic kidney disease (CKD) after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in the non-cancer population. Across various populations, CKD is associated with an elevated risk of cancer incidence and cancer death compared with people without CKD, although the risks are cancer site-specific. Higher risk of cancer is detectable in mild CKD [estimated glomerular filtration rate (eGFR) 60-89 mL/min/1.73 m(2)], although this risk is more obvious if sensitive markers of kidney disease are used, such as cystatin C. Independent of eGFR, albuminuria is associated with increased risk of site-specific cancer incidence and death. Here, we explore the potential mechanisms for the increased risk of cancer observed in CKD, including patient factors (shared risks such as cardiometabolic disease, obesity, smoking, diet, lifestyle and environment), disease (genetic, inflammatory and infective) and treatment factors. In particular, we discuss the ways in which renal adverse events associated with conventional chemotherapies and newer systemic anti-cancer therapies (including targeted and immunotherapies) may contribute to worse cancer outcomes in people with CKD. Finally, we review the potential benefits of acknowledging increased risk of cancer in risk prediction tools used for the management of CKD.

Automated summary

Cancer risk is higher in patients with chronic kidney disease (CKD), especially those with lower estimated glomerular filtration rate (eGFR) or albuminuria. The increased risk of cancer in CKD is influenced by various factors including patient characteristics, disease factors, and treatment factors. Renal adverse events associated with chemotherapy and newer anti-cancer therapies may contribute to worse cancer outcomes in CKD patients. Acknowledging the increased cancer risk in CKD can potentially improve management.